{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Powder&page=3",
    "query": {
      "intervention": "Study Powder",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Powder&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+Powder&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T10:49:52.774Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05510115",
      "title": "Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Polycystic Kidney, Autosomal Dominant"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-11-18",
      "completion_date": "2026-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05510115"
    },
    {
      "nct_id": "NCT05612035",
      "title": "Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension",
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Frespaciguat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 129,
      "start_date": "2023-03-16",
      "completion_date": "2029-10-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 18,
      "location_summary": "San Francisco, California • Aurora, Colorado • Sebring, Florida + 15 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Sebring",
          "state": "Florida"
        },
        {
          "city": "Elk Grove Village",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05612035"
    },
    {
      "nct_id": "NCT04406649",
      "title": "A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine",
        "Migraine With Aura",
        "Migraine Without Aura"
      ],
      "interventions": [
        {
          "name": "Dihydroergotamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Satsuma Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 482,
      "start_date": "2020-09-14",
      "completion_date": "2023-01-16",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 44,
      "location_summary": "Encino, California • Long Beach, California • Los Alamitos, California + 40 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04406649"
    },
    {
      "nct_id": "NCT05136404",
      "title": "A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Selpercatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loxo Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2021-12-03",
      "completion_date": "2022-03-14",
      "has_results": true,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136404"
    },
    {
      "nct_id": "NCT06630806",
      "title": "A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasma Cell Myeloma Refractory"
      ],
      "interventions": [
        {
          "name": "SAR446523",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2024-10-30",
      "completion_date": "2031-05-16",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630806"
    },
    {
      "nct_id": "NCT01156792",
      "title": "Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FP 100",
          "type": "DRUG"
        },
        {
          "name": "GSK2190915 100",
          "type": "DRUG"
        },
        {
          "name": "GSK2190915 300",
          "type": "DRUG"
        },
        {
          "name": "montelukast",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "FP/SAL 100/50",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "12 Years and older · Female only"
      },
      "enrollment_count": 162,
      "start_date": "2010-09",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01156792"
    },
    {
      "nct_id": "NCT04673175",
      "title": "Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pneumonia",
        "Hematologic Malignancy",
        "Pseudomonas Aeruginosa Infection",
        "Bacteremia",
        "Hematopoietic Stem Cell Transplant (HSCT)"
      ],
      "interventions": [
        {
          "name": "Ceftolozane / Tazobactam Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2023-01-10",
      "completion_date": "2025-03-16",
      "has_results": true,
      "last_update_posted_date": "2026-01-21",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04673175"
    },
    {
      "nct_id": "NCT00230607",
      "title": "Study of the Effects of Fabrazyme Treatment on Lactation and Infants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fabry Disease",
        "Alpha Galactosidase A Deficiency"
      ],
      "interventions": [
        {
          "name": "agalsidase beta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 7,
      "start_date": "2006-05-28",
      "completion_date": "2024-02-09",
      "has_results": true,
      "last_update_posted_date": "2024-04-10",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 3,
      "location_summary": "Decatur, Georgia • Fairfax, Virginia • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00230607"
    },
    {
      "nct_id": "NCT05703607",
      "title": "A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Shingles",
        "Herpes Zoster Infection",
        "Human"
      ],
      "interventions": [
        {
          "name": "Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 1: PF-07915234: VZV modRNA Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 2: PF-07921188: VZV modRNA Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 3: PF-07921186: VZV modRNA Suspension for Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shingrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 484,
      "start_date": "2023-01-25",
      "completion_date": "2025-09-23",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 35,
      "location_summary": "Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05703607"
    },
    {
      "nct_id": "NCT01086410",
      "title": "Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Furoate/GW642444 Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 185,
      "start_date": "2010-03",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2017-01-18",
      "last_synced_at": "2026-10-30T10:49:52.774Z",
      "location_count": 4,
      "location_summary": "Cypress, California • Huntington Beach, California • Oklahoma City, Oklahoma + 1 more",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01086410"
    }
  ]
}